Re: Anacetrapib Officially Bites the Dust
in response to
by
posted on
Oct 27, 2017 03:51PM
The way I look at anacea-ei-ei-o-trib's failure....okay, whoop deee do. Its a positive and a negative. On the positive side, obviously its good for us, because if RVX-208 gets approved, then its less competition. But on the down side it shows how hard it is to get a CVD drug/compound through the clinical trial phase and to the finish line.
Anacetrapib actually made it to the finish line, and still was deemed not viable as a New Drug. So I can understand a Bio tech centred fund manager having pause about Resverlogix.